Clinical Trial Update: An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Open-label, multi-center Phase I/IIa dose-escalation study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of ACR246 in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ACR246

Snippet

Sponsor: Hangzhou Adcoris Biopharmacy Co., Ltd | Conditions: Advanced Solid Tumors | Phase 1 | Status: RECRUITING